Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

The mouse, dog, and monkey toxicity data on 30 drugs was retrospectively analyzed in comparison with the actual clinical dose schedules used in man. Animal dose schedules were converted to the human schedule and comparisons were made of the human dose versus the large animal toxic dose low, toxic dose high, and lethal dose, the lethal doses for 10% and 90% of normal mice, and the optimal dose in tumor-bearing mice. If the starting dose in Phase 1 clinical trials had been selected by calculating one-third of the toxic dose low (in mg/sq m) in the most sensitive large animal species, 5 of the 30 drugs would have produced significant toxicity in the first patient. The lethal doses for 10 and 90% of normal mice and the optimal dose in L1210-bearing mice were found to offer good quantitative prediction of human toxicity. Determination of a safe and practical starting dose for Phase 1 studies should take into account not only dog and monkey data but also toxicology data in normal and tumor-bearing mice.

[1]  W. Whitmore,et al.  Mithramycin in metastatic urogenital cancer. , 1967, The Journal of urology.

[2]  D. Pinkel The use of body surface area as a criterion of drug dosage in cancer chemotherapy. , 1958, Cancer research.

[3]  Mastrangelo Mj,et al.  Phase I study of ICRF-159 (NSC-129943) in human solid tumors. , 1973 .

[4]  H. Bisel,et al.  Clinical studies with tubercidin administered by direct intravenous injection. , 1970, Cancer research.

[5]  Homan Er Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. , 1972 .

[6]  Frei E rd,et al.  Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971 .

[7]  D. Rall,et al.  The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.

[8]  H. Hansen,et al.  Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. , 1972, Cancer chemotherapy reports.

[9]  D. Rall,et al.  Clinical studies of dichloromethotrexate (NSC 29630) , 1965, Clinical pharmacology and therapeutics.

[10]  R. Adamson METABOLISM OF ANTICANCER AGENTS IN MAN , 1971, Annals of the New York Academy of Sciences.

[11]  V. Vaitkevicius,et al.  Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses). , 1972, Cancer chemotherapy reports.

[12]  G. Robertson,et al.  Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. , 1968, Canadian Medical Association journal.

[13]  G. Falkson Methyl-GAG (NSC-32946) in the treatment of esophagus cancer. , 1971, Cancer chemotherapy reports.

[14]  J. Finklestein,et al.  5-Azacytidine: a new active agent for the treatment of acute leukemia. , 1973, Blood.

[15]  G. Bryan,et al.  Preliminary clinical trial and the physiologic disposition of 4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide in man. , 1969, Cancer research.

[16]  A. Owens Predicting anticancer drug effects in man from laboratory animal studies. , 1962, Journal of Chronic Diseases.

[17]  T. Grage,et al.  Clinical studies with tubercidin administered after absorption into human erythrocytes. , 1970, Cancer research.

[18]  Luce Jk,et al.  Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). , 1970 .

[19]  Bergsagel De,et al.  Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388). , 1971 .

[20]  E. Freireich,et al.  Cytosine arabinoside (NSC-63878) therapy for acute leukemia in adults. , 1969, Cancer chemotherapy reports.

[21]  E J Freireich,et al.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.

[22]  H. Skipper,et al.  Experimental Evaluation of Potential Anticancer Agents: XII. Quantitative Drug Response of the SA180, CA755, and Leukemia L1210 Systems to a “Standard List” of “Active” and “Inactive” Agents , 1963 .

[23]  A. Guarino,et al.  Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: protocols of the laboratory of toxicology. , 1973, Cancer chemotherapy reports. Part 3.

[24]  E. Frei,et al.  Phase I and phototoxicity studies of pseudourea (NSC-56054). , 1971, Cancer chemotherapy reports.

[25]  E. Henderson,et al.  High dose daunorubicin (NSC-83142) in the treatment of advanced acute myelogenous leukemia. , 1972, Cancer chemotherapy reports.

[26]  H. Skipper,et al.  Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. , 1963, Cancer research.

[27]  A. Guarino,et al.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). , 1970, Cancer chemotherapy reports.

[28]  J. Edmonson,et al.  Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. , 1965, Cancer research.

[29]  B. Brodie Part VI. Difficulties in extrapolating data on metabolism of drugs from animal to man , 1962 .

[30]  C. Coltman,et al.  Phase I experience with emetine hydrochloride (NSC 33669) as an antitumor agent , 1971, Cancer.

[31]  F. Ansfield,et al.  Phase I study of dibromodulcitol (NSC-104800). , 1971, Cancer chemotherapy reports.

[32]  J. Finklestein,et al.  Evaluation of a high dose cyclophosphamide regimen in childhood tumors , 1969, Cancer.

[33]  For April. , 1903 .

[34]  W. Regelson,et al.  Clinical experience with methylglyoxal bis (guanylhydrazone) dihydrochloride: a new agent with clinical activity in acute myelocytic leukemia and the lymphomas. , 1963, Cancer chemotherapy reports.

[35]  J. Blom,et al.  Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-67574) plus prednisone in advanced childhood acute lymphocytic leukemia. , 1972, Cancer chemotherapy reports.

[36]  I. Todd,et al.  The Design of Clinical Trials in Cancer Therapy , 1972, British Journal of Cancer.

[37]  E. Homan Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man. , 1972, Cancer chemotherapy reports. Part 3.

[38]  R. Geran,et al.  PROTOCOLS FOR SCREENING CHEMICAL AGENTS AND NATURAL PRODUCTS AGAINST ANIMAL TUMORS AND OTHER BIOLOGICAL SYSTEMS , 1972 .